Kidney Cancer

An expert provides answers to readers’ questions regarding different aspects of the kidney cancer experience, such as protein intake and clinical trials.

An expert provides answers to pressing questions regarding different aspects of a kidney cancer journey, including stage, grade and treatment options.

At the 2024 ESMO Congress, CURE® spoke with an expert about Fotivda and certain challenges patients may experience, such as side effects.

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo.

Among patients with previously treated advanced clear cell renal cell carcinoma (RCC) Welireg continued to show some benefits, though not to overall survival.

One expert explained why ‘it’s very important to know what’s going on’ with regard to new renal cell carcinoma treatments.

Afinitor did not improve relapse-free survival in patients with non-clear cell renal cell carcinoma — a kidney cancer subtype linked to poor prognosis.

Walking up and down the street a few times a day can help prevent patients with kidney or bladder cancers from becoming deconditioned.

Understanding how I fit in matters to me but figuring out my identity in the cancer space is not always easy.

Considering nutrition and frailty earlier on may help patients achieve better health-related quality of life during kidney cancer and bladder cancer.

Relapse outcomes were similar in patients with high-risk renal cell carcinoma treated with Opdivo and with observation before and after surgery.

An analysis of more than 500 patients with advanced kidney cancer treated with Welireg broke down the rates of moderate to severe side effects.

Dana Frost, a cancer survivor and grief advocate, said writing about survivors’ guilt and connecting with others feeling the same way was therapeutic.

The Food and Drug Administration granted a fast track designation to ADI-270, an off-the-shelf CAR-T cell therapy for clear cell renal cell carcinoma.

I was diagnosed with kidney cancer and pancreatic neuroendocrine tumors two years ago, but I’ve learned a lifetime of lessons since.

Patients who received systemic therapy at the end of life did not have longer overall survival averages than those who did not receive therapy at end of life.

Learning that I had cancer — melanoma and renal cell carcinoma — made me feel like I lost something, but I keep looking ahead.

During my time with cancer, I've come across words associated with cancer that I don't like and some that I appreciate.

The Food and Drug Administration granted a Biologics License Application for subcutaneous Opdivo for potential approval.

This is the poem I wrote to help myself cope with my new diagnosis. It served as a reminder that I was resilient.

For decades, researchers have been seeking a therapy to improve outcomes for patients with clear cell renal cell carcinoma who underwent a nephrectomy.

Anxiety over scans makes sense, but isn’t there more anxiety about other cancer tests, too?

Across disease stages, Black patients with renal cell carcinoma experience worse survival outcomes than White patients, research has shown.

Patients with inoperable kidney cancer saw significant results in local control and cancer-specific survival with stereotactic ablative body radiotherapy.

Subcutaneous administration of Opdivo, could increase efficiency and reduce wait times for patients, as one expert explains to CURE®.

When life hands you cancer lemons, what flavored lemonade do you make?

Researchers have determined distinguishing characteristics of TFE3-rearranged renal cell carcinoma.

Artificial intelligence platform ChatGPT is capable of providing “widely understandable and accessible” answers about kidney cancer, but experts express caution.

Welireg outperformed Afinitor in time to disease progression and patient-reported quality of life in the treatment of metastatic clear cell renal cell carcinoma.

Real-world data demonstrated that knowing a patient’s stage and subtype of renal cell carcinoma, a type of kidney cancer, may provide cancer teams with the information needed to determine potential prognosis and recurrence risk.